South Delhi Pharma, New Delhi, India
ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use.
SDP are here to serve you through the quality pharmaceutical products as per your needs. Established in the year 1996, we have earned a global reputation in the market. Owing to superior quality widest range of Anti Cancer medicines.
ENHERTU is a prescription medicine. ENHERTU is used to treat (HER2)-positive breast cancer.
INDICATIONS AND USAGE
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DOSAGE FORMS & STRENGTHS
For injection: 100 mg lyophilized powder in a single-dose vial
Manufactured By: Daiichi Sankyo, Inc.
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “ENHERTU ® (fam-trastuzumab deruxtecan-nxki) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Trastuzumab deruxtecan also known as fam-trastuzumab deruxtecan and sold under the brand name Enhertu, is a medication used for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Trastuzumab deruxtecan is an antibody-drug conjugate that includes a human epidermal growth factor receptor 2 (HER2)-directed antibody trastuzumab and a topoisomerase I inhibitor conjugate deruxtecan (a derivative of exatecan). It was approved for use in the United States in December 2019.
Reviews
There are no reviews yet.